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Identification of the T cell immunoglobulin mucin-domain containing (Tim) gene family 
introduced a new family of cell surface molecules that is involved in the regulation of 
immune responses. We previously demonstrated that Tim-3 is expressed on terminally 
differentiated T helper (Th)1 cells, and serves to regulate Th1 immune responses. Here, we 
describe the identification and function of Tim-2, a novel member of the Tim gene family. In 
contrast with Tim-3, we demonstrate that Tim-2 is expressed preferentially in differentiated 
Th2 cells. Blockade of the Tim-2/Tim-2 ligand interaction, by administration of soluble Tim-2 
fusion protein (Tim-2 immunoglobulin [Ig]), results in T cell hyperproliferation and the 
production of Th2 cytokines. Administration of Tim-2 Ig during the induction phase reduces 
the severity of experimental autoimmune encephalomyelitis, a Th1-mediated autoimmune 
disease model of multiple sclerosis. We propose that Tim-2, an orthologue of human Tim-1, 
is critical for the regulation of Th2 responses during autoimmune inflammation.
 
Activation of naive CD4
 
 
 
 T cells drives their
differentiation into two phenotypically and
functionally distinct subsets, Th1 or Th2,
that differ in their cytokine production and
effector functions (1–4). Th1 cells produce
IFN-
 
 
 
 and TNF-
 
 
 
 and are involved in the
clearance of intracellular pathogens and the
induction of autoimmune diseases (5). Th2
cells that produce cytokines, including IL-4
and IL-10, clear extracellular pathogens (e.g.,
helminths), regulate autoimmunity, and play
critical roles in the induction of asthma and
atopy (4, 6). Only recently have cell surface
markers been identified that clearly distin-
guish Th1 and Th2 cells. Th1 and Th2 cells
show a quantitative difference in chemokine
and costimulatory receptor expression (7–9).
Using an antibody screening approach, we
identified cell surface molecule T cell immu-
noglobulin mucin-domain containing (Tim)-3
that is expressed specifically on the surface of
Th1, but not Th2, cells (10). Tim-3 belongs
to the novel Tim family of cell surface pro-
teins. The mouse gene family consists of eight
members (Tim-1 to Tim-8), whereas the hu-
man gene family consists of three members
(Tim-1, Tim-3, and Tim-4; reference 11).
All members share the characteristic structure
of an IgV, mucin, transmembrane, and cyto-
plasmic domains. The gene family plays a
critical role in the regulation of immune re-
sponses (10–14). Administration of soluble
Tim-3 Ig fusion protein resulted in hyper-
proliferation of Th1 cells, exacerbation of
autoimmunity, and prevention of transplan-
tation and high-dose tolerance induction
(10, 13, 14). Furthermore, the gene family
has been linked genetically to murine airway
hypersensitivity (a Th2-driven disease), and
polymorphic alleles of Tim-1 play a role in
susceptibility to human asthma (12). These
findings suggested that other Tim family
members have a role in regulating Th re-
sponses. Here, we have analyzed the expres-
sion and function of Tim-2. We demonstrate
that Tim-2 is expressed preferentially in Th2
cells, and blockade of the Tim-2/Tim-2
ligand interaction results in expansion of a Th2
response and attenuation of a Th1-mediated
autoimmune disease. We propose that Tim-2
plays an important role in the regulation of
Th2 immunity.
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RESULTS
Tim-2 is expressed preferentially in Th2 cells
 
Mouse Tim-2 shares the greatest degree of nucleotide se-
quence identity to mouse Tim-1 (85%). Tim-1 was identified
originally on African green monkey kidney cells as a hepatitis
A virus receptor, and later was found to be expressed on kid-
ney epithelial cells (15, 16). More recently, it has been dem-
onstrated that mouse Tim-1 also is expressed on the surface
of T cells, with a higher expression on Th2 differentiated
cells compared with Th1-type cells (17, 18). Given the se-
quence similarity, we were interested in investigating the ex-
pression profile of Tim-2. Using real-time quantitative PCR,
we studied the expression pattern of Tim-2 in various cell
populations. Low levels of Tim-2 were detected in unacti-
vated and activated CD4
 
 
 
 and CD8
 
 
 
 T cells (Fig. 1 A). Tim-2
expression was increased only marginally after polyclonal
stimulation of T cells with conalbumin A or anti-CD3/anti-
CD28 stimulation (Fig. 1 B); no detectable level of Tim-2
expression was observed in other cell types, including B cells,
macrophages, and dendritic cells (Fig. 1, A and B). Given the
expression of Tim-2 in T cells, we investigated whether
Tim-2, like Tim-3, was expressed differentially in Th1 versus
Th2 cells. High levels of Tim-2 expression were observed in
the long-term Th2 clone, D10G4, whereas little expression
was detected in the Th1 clone, AE7 (Fig. 1 C). To establish
the kinetics of Tim-2 expression during Th2 cell differentia-
tion, we generated CD4
 
 
 
 Th1 and Th2 cell lines from
DO11.10 TcR transgenic mice. We observed significant up-
regulation of Tim-2 expression during late-stage Th2 differ-
entiation in vitro, particularly after round III of stimulation
under Th2-inducing conditions (Fig. 1 C). Although low
levels of Tim-2 were detected in early rounds of Th1 polar-
ization, by three rounds of polarization in vitro, Tim-2 ex-
pression was not detected in fully differentiated Th1 cells
(Fig. 1 C). We next examined the pattern of Tim-2 expres-
sion in Th2 cells that were derived from BALB/c, C57BL/6,
and SJL/J mouse strains, which are biased genetically to in-
duce Th1 (SJL and C57BL/6) or Th2 (BALB/c) responses.
Tim-2 was up-regulated preferentially in Th2 cells from all
three strains (Fig. 1 D). Together, these data suggest that
Tim-2 is specifically up-regulated in Th2 cells, and is down-
regulated during Th1 differentiation. In the absence of a spe-
cific antibody to Tim-2, we determined whether Tim-2 is
expressed as a protein. We generated Tim-2 hemagglutinin A
(HA)–tagged T cell (TK-1 and EL-4) and non–T cell (CHO
and HEK-293) transfectants, and demonstrated that Tim-2 is
expressed on the cell surface (Fig. 1 E). Western blot analysis
of transfectants using an anti-HA–specific antibody demon-
strated that in contrast with normal rabbit IgG, the anti–HA-
tagged–specific antibody immunoblotted a broad band of
 
 
 
65–70 kD, which was consistent with the heavily glycosy-
lated Tim-2 molecule (Fig. 1 F; reference 19). In addition,
we have expressed Tim-2 as an Ig fusion protein (see Materi-
als and methods); this further supports the notion that Tim-2
is expressed as a functional protein.
Figure 1. Tim-2 is up-regulated in Th2 cells. The expression pattern of 
Tim-2 was examined in various cell populations using real-time quan-
titative RT-PCR. Tim-2 expression was examined and expressed relative 
to GAPDH expression. (A) Ex vivo SJL CD4 , CD8 , B220 , CD11b , and 
CD11c  cells were purified from spleen cells. RNA was extracted and 
cDNA was generated for real-time quantitative PCR. (B) Ex vivo SJL 
CD4 , CD8 , B220 , CD11b , and CD11c  cells were purified from 
spleen cells. CD4  and CD8  cells were activated with plate-bound 
anti-CD3/anti-CD28; B220 , CD11b , and CD11c  were activated by 
LPS and IFN- . 48 h after activation, RNA was extracted and cDNA was 
generated for real-time quantitative PCR. (C) D011.10 CD4  T cells 
were stimulated with OVA-peptide and APCs, in vitro under Th1 or 
Th2 polarizing conditions. At the end of each round of stimulation, 
RNA was extracted and cDNA was generated from Th1 and Th2 cells. 
(D) CD4  T cells from SJL, C57BL/6, and BALB/c mice were stimulated 
with plate-bound anti-CD3/anti-CD28 in vitro under Th1 or Th2 polar-
izing conditions. At the end of the first round of stimulation, RNA was 
extracted and cDNA was generated from Th1 and Th2 cells. (E) Tim-2 is 
expressed as a cell surface protein. T cell (EL-4 and TK-1) and non–T 
cell (CHO and 293) transfectants were stained with biotinylated anti-HA 
antibody, and streptavidin-PE as a secondary detection reagent. Cells 
were analyzed by flow cytometry for surface expression of Tim-2. Solid 
line represents the staining of Tim-2 transfectants and the dotted line, 
empty vector. (F) Tim-2 expression by Western blot. Lysates from Tim-2–
transfected CHO and HEK-293 cells were run on a 10% SDS-PAGE gel. 
Polyvinyldifluoride membranes were probed with anti-HA antibody or 
control normal rabbit IgG, followed by an HRP-conjugated anti–rabbit 
secondary antibody. 
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Tim-2 ligands are expressed on activated dendritic cells 
and macrophages
 
We next generated a Tim-2 Ig fusion protein to identify cell
populations expressing Tim-2 ligands. Tim-2 Ig consisted of
the IgV and mucin domains of Tim-2 fused to the human
IgG Fc tail. Unactivated splenic-derived cells did not express
the Tim-2 ligand. However, upon activation of APCs (B
cells, macrophages, and dendritic cells) with LPS and IFN-
 
 
 
,
a marked up-regulation of Tim-2 ligand expression was ob-
served (Fig. 2). A subset of activated B220
 
 
 
 and CD11b
 
 
 
cells was positive for Tim-2 ligand expression, whereas all
activated CD11c
 
 
 
 cells expressed the Tim-2 ligand (Fig. 2).
The Tim-2 ligand was not detected on CD3
 
 
 
 T cells, either
naive or activated by anti-CD3/anti-CD28 stimulation.
These data suggest that Tim-2 expressed on Th2 cells binds a
ligand that is expressed on activated APCs.
 
Administration of Tim-2 Ig results in hyperproliferation 
and Th2 cytokine production
 
To determine the function of the Tim-2/Tim-2 ligand in-
teraction during an autoimmune, inflammatory response,
SJL/J mice were immunized with proteolipid protein (PLP)
139–151 peptide emulsified in CFA and treated with Tim-2
Ig, or controls (human IgG [hIgG] or PBS). 10 d after im-
munization, spleen cells harvested from Tim-2 Ig–treated
mice demonstrated a pronounced level of basal proliferation
in the presence of media without the addition of any exoge-
nous antigen in vitro (Fig. 3 A). This proliferation was not
observed for cells harvested from control mice (Fig. 3 A).
Upon recall-stimulation with the immunizing antigen PLP
139–151, cells from control groups and the Tim-2 Ig–
treated group demonstrated a similar proliferative dose-
response curve (Fig. 3 B). These data suggest that Tim-2 Ig
administration results in the hyperactivation of cells in vivo,
such that they continue to proliferate in the absence of anti-
gen in vitro.
Supernatants from these cell cultures were analyzed 48 h
after restimulation by cytokine ELISA for the production of
IL-2, IFN-
 
 
 
, IL-4, and IL-10. Spleen cells from control
Figure 2. Tim-2 ligand is expressed on activated APCs. To determine 
the cell populations expressing Tim-2 ligands, we stained various cell 
populations with biotinylated Tim-2 Ig as follows: ex vivo BALB/c CD3 , 
B220 , CD11b , or CD11c  cells. Spleen cells from BALB/c mice were acti-
vated with conalbumin A (CD3 ) or LPS and IFN-  (B220 , CD11b  and 
CD11c ), were column purified using negative selection (CD3 ) or positive 
selection (B220 , CD11b , and CD11c ) and stained for Tim-2 ligand ex-
pression with biotinylated Tim-2 Ig (solid black line), or biotinylated hIgG 
(shaded curve) as a control, followed by streptavidin-PE as a secondary 
reagent for detection.
Figure 3. Administration of Tim-2 Ig induces hyperproliferation 
and production of Th2 cytokines. (A) Spleen cells from SJL/J mice immu-
nized with PLP 139–151 peptide emulsified in CFA, and treated in vivo with 
Tim-2 Ig, or hIgG or PBS as controls, were cultured in vitro for 48 h without 
peptide restimulation. Proliferation was measured in triplicate wells after 
48 h by 3[H]-thymidine incorporation. Data shown are for individual mice, 
representative of seven experiments for proliferation. (B) Spleen cells taken 
from immunized, fusion-protein–treated mice were stimulated in vitro 
with 0–100  g of PLP 139–151 peptide. Proliferation was measured after 
48 h.  , PBS;  , hIgG;  , Tim-2 Ig treated. (C) Supernatants were taken at 
48 h from in vitro cultures of spleen cells restimulated with PLP 139–151 
peptide, and cytokine ELISAs for IL-2, IL-4, IL-10, and IFN-  were performed. 
 , PBS;  , hIgG;  , Tim-2 Ig treated. Data shown for individual mice; 
representative of five experiments for cytokines. 
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groups—treated with hIgG or PBS—demonstrated the pre-
dicted Th1 type response with production of IL-2 and IFN-
 
 
 
(Fig. 3 C). Spleen cells from Tim-2 Ig–treated mice se-
creted high levels of IL-2, which was consistent with the
high level of basal proliferation that was observed. However,
in contrast with control groups, spleen cells from Tim-2 Ig–
treated mice demonstrated little or no IFN-
 
 
 
 production
(Fig. 3 C). Surprisingly, there was increased production of
hallmark Th2 cytokines, IL-4 and IL-10, in the Tim-2 Ig–
treated groups, even when immunized with PLP emulsified
in CFA, a known inducer of Th1 (IFN-
 
 
 
) responses (Fig. 3
C). We previously proposed that an interaction between
Tim-3 and its ligand serves to down-regulate the Th1 re-
sponse, and that administration of Tim-3 Ig blocks this in-
hibitory interaction, and results in the expansion and hyper-
proliferation of Th1 cells (13). Administration of Tim-2 Ig
results in similar hyperproliferation as observed with Tim-3
Ig. However, in contrast with Tim-3 Ig, Tim-2 Ig results in
the expansion of a Th2 cytokine response.
Because spleen cells from Tim-2 Ig–treated mice showed
higher basal proliferation (Fig. 3 A), we wanted to analyze
which cells were involved in the enhanced proliferative and
cytokine response. T cells and APCs from immunized con-
trol and Tim-2 Ig–treated mice were purified, cultured sepa-
rately, or recombined. Separation of cell subsets and recom-
bination of T cells and APCs from Tim-2 Ig–treated or
control mice demonstrated that the hyperproliferative re-
sponse was dependent on T cells from Tim-2 Ig–treated
mice and not macrophages or B cells. T cells from Tim-2
Ig–treated mice, even when recombined with B cells or
macrophages from control animals, reconstituted the hyper-
proliferative phenotype (Fig. 4 B). Furthermore, recombina-
tion of T cells from control mice with APCs from Tim-2
Ig–treated mice did not reconstitute the proliferative re-
sponse. This indicated that the hyperproliferative response is
dependent on T cells from Tim-2 Ig–treated mice (Fig. 4 B).
 
Blockade of the Tim-2/Tim-2 ligand interaction 
during the induction phase of experimental 
autoimmune encephalomyelitis
 
The production of Th1 cytokines by myelin-specific T cells
has been associated with the development of experimental
autoimmune encephalomyelitis (EAE), whereas the secre-
tion of Th2 cytokines has been associated with disease regu-
lation and recovery (20, 21). Thus, the onset and progression
of disease is dependent, in part, on a balance between the
two responses. Given that Tim-2 Ig administration resulted
in the skewing of an immune response toward a Th2 pheno-
type, we hypothesized that Tim-2 Ig treatment may pro-
mote expansion of Th2 cells which could regulate the devel-
opment of EAE. We immunized SJL/J mice with the
encephalitogenic peptide, PLP 139–151, in CFA to induce
EAE (22). Immunized mice were treated with four doses of
Tim-2 Ig, hIgG, or PBS, every other day from day 0 to day
8. Immunized mice that were treated with hIgG or PBS
demonstrated a typical EAE disease course with the onset of
clinical symptoms between days 10 and 12, followed by peak
clinical disease around day 17 (Fig. 5 A). In contrast, treat-
ment with Tim-2 Ig resulted in a delay in the onset of clini-
cal signs; these Tim-2 Ig–treated mice displayed only mild
signs of paralysis, and demonstrated peak clinical disease only
after day 22 (Fig. 5 A). The administration of a single dose of
Tim-2 Ig just before the onset of disease also was sufficient
to reduce the clinical signs of EAE (Fig. 5 B). Histologic ex-
Figure 4. Hyperproliferation of cells from Tim-2 Ig–treated mice is 
mediated by an interaction between T cells from Tim-2 Ig–treated 
mice and APCs. (A) Individual cell populations: CD3  T, B220  B, and 
CD11b  cells were purified from the spleens of immunized, and Tim-2 
Ig or hIgG–treated SJL/J mice. Splenocytes (5   105), T cells (105), B cells 
(2   105), and CD11b  cells (2   105) were cultured individually, and the 
proliferative responses were measured 48 h later by 3[H]-thymidine incor-
poration in triplicate wells. Results are represented as average for four 
mice combined, representative of three experiments. (B) Recombined cell 
populations: CD3  T, B220  B, and CD11b  cells were purified from the 
spleens of immunized, and Tim-2 Ig or hIgG–treated SJL/J mice. T cells 
(105) from Tim-2 Ig or hIgG–treated mice were incubated in the presence 
of 2   105 B cells or 2   105 CD11b  cells purified from Tim-2 Ig and 
hIgG–treated mice; the proliferative response was measured 48 h later by 
3[H]-thymidine incorporation in triplicate wells. Results are represented as 
average for four mice combined, representative of three experiments. 
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amination of brain and spinal cords demonstrated a signifi-
cant reduction in the number of inflammatory lesions in the
meninges and parenchyma in mice that were treated with
Tim-2 Ig (mean total inflammatory foci 
 
 
 
 SD 
 
 
 
 53 
 
 
 
 17)
in comparison with control animals (108 
 
 
 
 30; Fig. 5 C).
Taken together, these results suggest that blockade of the
Tim-2/Tim-2 ligand interaction results in the expansion of a
Th2 response, even within a Th1-immune setting.
 
DISCUSSION
 
The identification of Tim-3 not only identified a Th1-spe-
cific cell surface molecule, but also introduced a new family
of genes, the Tim gene family. Here we begin to elucidate
the role of a novel member of the Tim gene family, Tim-2.
We demonstrate that in contrast with Tim-3, a known Th1
cell surface marker, Tim-2 seems to be up-regulated prefer-
entially in Th2 cells and down-regulated in Th1 cells. The
use of a soluble Tim-2 fusion protein explores the in vivo
role of the Tim-2/Tim-2 ligand interaction in an autoim-
mune setting.
Quantitative mRNA analysis of lymphoid cell popula-
tions from mice demonstrated that Tim-2 expression was
detected at low levels in naive CD4
 
 
 
 and CD8
 
 
 
 T cells. Af-
ter activation, CD4
 
 
 
 and CD8
 
 
 
 T cells demonstrated up-
regulation in Tim-2 expression. Further examination of Th1
and Th2 differentiated cells revealed that Tim-2 was ex-
pressed significantly more in Th2 clones and lines than in
Th1 clones and lines. Thus, in contrast with Tim-3, which is
expressed on terminally differentiated Th1 cells, Tim-2 is
expressed at low levels in naive and activated T cells and
Figure 5. Tim-2 Ig delays the onset and decreases the severity of 
EAE. (A) SJL/J mice were immunized for the induction of EAE with PLP 
139–151 emulsified in CFA, and treated with five injections of Tim-2 Ig every 
other day for 8 d with Tim-2 Ig ( ), hIgG ( ), or PBS ( ) as controls. Mice 
were examined daily for signs of EAE. Mice treated with Tim-2 Ig demon-
strated significantly lower (P   0.01) cumulative disease scores when 
compared with PBS and hIgG controls. (B) SJL/J mice were immunized for 
the induction of EAE with PLP 139–151 emulsified in CFA, and treated 
with only one injection on day 8 with Tim-2 Ig ( ), hIgG ( ), or PBS ( ) 
as controls. Mice were examined daily for signs of EAE. Mice treated with 
Tim-2 Ig demonstrated significantly lower (P   0.01) cumulative disease 
scores when compared with PBS and hIgG controls. (C) Representative 
fields of cerebellar white matter demonstrate typical perivascular mono-
nuclear cell infiltrates in control PBS- and hIgG-treated, but not the Tim-2 
Ig–treated, SJL mice immunized for EAE. Luxol fast blue-hematoxylin and 
eosin stains. Original magnification, 80. 
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preferentially up-regulated during Th2 differentiation. Tim-2
demonstrates a far more restricted expression pattern in
comparison with mouse Tim-1 which is found on all acti-
vated T cells, Th1 and Th2 cells (although at higher levels
on Th2 cells), and epithelial cells (15–17, 23). Therefore, al-
though mouse Tim-1 shares the greatest sequence identity
with human Tim-1 (as suggested by the nomenclature),
mouse Tim-2 may share more functional characteristics with
human Tim-1. Therefore, mouse Tim-2 also could be con-
sidered as an orthologue of human Tim-1. The high expres-
sion of Tim-2 in late Th2 differentiation also is interesting
given the association of the Tim gene family with the regu-
lation of Th1 versus Th2 responses. Given the late expres-
sion of Tim-2 during Th2 differentiation, it is probable that
the in vivo role of Tim-2 is more important during the ef-
fector phase of an immune response rather than the initial
differentiation phase.
Using an expression cloning approach, Tim-2 was iden-
tified as a potential ligand for the semaphorin family member
Sema4a (19). Using anti-Sema4a antibody,
 
 
 
Kumanogoh et
al. demonstrated expression of Sema4a predominantly on
dendritic cells and B cells, with up-regulation upon activa-
tion. They also identified low levels of Sema4a expression on
the surface of activated T cells (19). Although we have dem-
onstrated that Tim-2 ligand is expressed on activated APCs
by staining with Tim-2 Ig, in contrast with Kumanogoh et
al., we did not detect any expression of Tim-2 ligand on T
cell populations (naive or activated). This could reflect con-
formational or expression differences of Sema4a in T cells
that are not recognized by Tim-2 Ig. Also, it is highly likely
that Tim-2 binds a variety of ligands and that Tim-2 Ig is
more specific for ligands other than Sema4a on the surface of
activated APCs. Our data on the expression pattern of Tim-2
on differentiated Th2 cells suggests that the Tim-2/Tim-2
ligand interaction predominantly involves associations be-
tween Th2 cells and activated APCs.
Based on the mechanistic paradigm proposed for Tim-3,
it is possible that the Tim-2/Tim-2 ligand interaction also
may be inhibitory, and thus, cross-linking of Tim-2 on Th2
cells may down-regulate the Th2 response. This would sug-
gest that the administration of Tim-2 Ig would block the en-
dogenous interaction between Tim-2 and its ligand, and al-
low for the expansion of Th2 cells and cytokines. In keeping
with this, administration of Tim-2 Ig during a Th1-biased
immune response resulted in the hyperproliferation of T
cells and the production of Th2 cytokines. If, as our data
suggest, the Tim-2/Tim-2 ligand interaction is inhibitory,
blockade of this interaction during the induction phase
would allow for the expansion of Th2 cells, and therefore,
affect the EAE disease course. Treatment of mice with Tim-2
Ig during the induction phase of EAE reduced the severity
of clinical and histologic disease. Consistent with this, ad-
ministration of a blocking antibody to Sema4a (a Tim-2
ligand) resulted in a reduced Th1 response and inhibition of
myelin oligodendrocyte glycoprotein–induced EAE (19).
Furthermore, recent work with the Sema4a knockout
mouse demonstrated a defect in establishing Th1, but not
Th2, responses (24). Thus, if the Tim-2/Sema4a interaction
served to down-regulate a Th2 response, blocking this inter-
action would result in inhibition of a Th1 response, as ob-
served with anti-Sema4a antibody or by administration of
Tim-2 Ig during EAE. Like Tim2, Sema4a may have other
ligands, and the blockade of Sema4a and Tim-2 may not be
equivalent. We recently demonstrated that in contrast with
Tim-2, Tim-1 interacts specifically with another Tim family
member, Tim-4 (18). Umetsu and colleagues demonstrated
that cross-linking Tim-1 on the surface of T cells stimulates
T cell expansion (17). Furthermore, we show that adminis-
tration of high amounts of Tim-4 Ig in the presence of low
levels of anti-CD3/anti-CD28 stimulation enhances T cell
proliferation (18). Taken together, we suggest that the Tim-
1/Tim-4 interaction has the potential to costimulate T cell
expansion (17, 18). Although Tim-1 and Tim-2 are very
similar molecules and closely related, their intracellular tails
are significantly different. Tim-2 shares only 56% identity
with Tim-1 in the cytoplasmic tail, and contains six extra
amino acids in the COOH-terminal end of the tail, which
contains an additional tyrosine phosphorylation motif. If
Tim-1 and Tim-2 turn out to be functionally different, we
suggest that the differences in the intracellular tail may ex-
plain, in part, their different mechanisms of action. Our data
and those of Kumanogoh and colleagues support our pro-
posal that Tim-2 serves to regulate a Th2 response negatively
in an autoimmune setting. However, further study is re-
quired to determine conclusively that Tim-2 Ig is not an ag-
onist promoting a Th2 response.
In addition to our observations of the role of Tim-2 in an
autoimmune Th1 setting, Tim-2 also may have a role in
pathogenic Th2 responses. Human Tim-1 initially was iden-
tified as a hepatitis A viral cellular receptor, and epidemio-
logic studies have shown that infection with hepatitis A virus
(HAV) is associated with protection against asthma and aller-
gies (23). If, like Tim-2, human Tim-1 is expressed on the
surface of Th2 cells, HAV might bind to Tim-1 and elimi-
nate or block Th2 effector functions. Consistent with this hy-
pothesis, polymorphic alleles of human Tim-1 have been
identified, and a deletion of six amino acid residues in the
mucin domain of Tim-1 has demonstrated strong linkage
with HAV infection and protection against asthma (25). Fur-
ther investigation will be required to identify the role of
Tim-2 in productive and pathogenic Th2 immune responses.
These data, in conjunction with our understanding of
Tim-3 and Tim-1, further support a crucial role for the Tim
family of genes in the differential regulation of Th1 and Th2
responses, and hence, their potential as therapeutic targets in
various immune-mediated diseases.
 
MATERIALS AND METHODS
 
Th1 and Th2 cell lines and clones.
 
AE7, a pigeon cytochrome 
 
c
 
–spe-
cific, I-Ek–restricted Th1 clone, and D10G4, a conalbumin A–specific, I-A-k–
restricted Th2 clone, were maintained as described previously (10). CellsJEM VOL. 202, August 1, 2005 443
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were maintained in DMEM supplemented with 0.1 mM nonessential amino
acids, sodium pyruvate (1 mM), L-glutamine (2 mM), MEM essential vita-
min mixture (1 ), penicillin (100 U/ml), streptomycin (100 U/ml), genta-
micin (0.1 mg/ml), 10% heat-inactivated FBS (BioWhittaker, Inc.), asparagine
(0.1 mM), folic acid (0.1 mg/ml), 2-mercaptoethanol (5   10 5 M) (Sigma-
Aldrich), 0.6% T cell growth factor (T-Stim, Collaborative Biomedical Re-
search), and 0.06% recombinant IL-2. Cells were maintained in a rest-stimu-
lation protocol (stimulation media is complete medium without T-Stim and
recombinant IL-2) as described. DO11.10 TcR transgenic Th1/Th2 cell
lines were maintained in the same complete medium, and were restimulated
with irradiated BALB/cJ spleen cells and OVA 323–339 peptide (10  g/ml,
Quality Controlled Biochemicals) in the presence of recombinant IL-12 and
anti–IL-4 (Th1), or IL-4 and anti–IL-12 (Th2). RNA was extracted from
cells and converted to cDNA for use in quantitative Taqman RT-PCR.
Quantitative TaqMan RT-PCR. RNA was reverse transcribed to
cDNA. Real-time RT-QPCR was performed using the TaqMan strategy
(Applied Biosystems). The expression levels of Tim-2 and internal reference
GAPDH were measured by multiplex PCR using probes labeled with
6-carboxyfluorescein (FAM) or 6-carboxyrhodamine (VIC; Applied Bio-
systems), respectively. The primers and probes were designed using Primer
Express v1.0 software (Applied Biosystems). The Tim-2 primer/probe se-
quences are as follows: FAM probe: 5 -ACAGCTGCCTGCCCAGTG-
CCC-3 ; forward primer: 5 -GCCGGTGGACCTCAGTTTC-3 ; reverse
primer: 5 -TGGGAGCCAGCACAGATCA-3  (Applied Biosystems). The
simultaneous measurement of Tim-2–FAM and GAPDH–VIC permitted
normalization of the amount of cDNA added per sample. PCRs were per-
formed using the Taqman Universal PCR Master Mix and the ABI PRISM
7700 Sequence Detection System. Relative gene expression levels were de-
termined as described previously (13).
Generation of cell lines expressing hemagglutinin A–tagged Tim-2.
Splenocytes from an SJL/J mouse were activated with concanavalin A, 1  g/
ml (Sigma-Aldrich), for 48 h. Total RNA was extracted with TRIzol reagent
(Invitrogen), and cDNA was synthesized using Superscript II reverse tran-
scriptase enzyme (Invitrogen). The Tim-2 cDNA lacking the first 63 nucle-
otides that encode signal peptide was generated by PCR using PfuUltra High-
Fidelity DNA polymerase (Stratagene). The primers used were: forward, 5 -
CATACAGCAGTGCAGGGGCTGG-3 ; reverse, GTAGGTCGACTAG-
GACTCTTCTTCGGGGTAAGG-3  with SalI site as overhang at the 5 
end. After confirming the DNA sequence, the PCR product was cloned be-
tween SmaI and SalI sites into the pDisplay vector containing a signal peptide
and HA-tag (Invitrogen), and the open reading frame was confirmed. CHO
and 293 cells were transfected with the above construct using Genejuice
transfection reagent (Novagen), whereas TK-1 and EL-4 cells were trans-
fected by electroporation. 48 h after transfection, the transfectants were cul-
tured in medium containing 1.0 mg/ml G418. Cells that survived the G418
selection were analyzed by flow cytometry using a biotinylated anti-HA anti-
body and streptavidin-PE as a detection reagent. Sorted cells were expanded
in G418-containing medium and examined for surface expression of Tim-2.
Western blot analysis. Cells were harvested and lysed in lysis buffer (20
mM Tris, pH 8.0, 150 mM NaCl, 1% Triton, 1% glycerol, 2 mM NaVO4,
2 mM leupeptin, 2 mM pepstatin A, 2 mM chymostatin). Protein concen-
tration was determined using Coomassie Plus Protein Assay Reagent (Pierce
Chemical Co.) and  50  g was separated by 10% SDS-PAGE. Polyvi-
nyldifluoride blots were blocked with 5% (wt/vol) nonfat dry milk and
probed with anti-HA tag rabbit polyclonal IgG or normal rabbit IgG (Up-
state Biotechnology) followed by HRP-conjugated goat anti–rabbit IgG
secondary antibody (Upstate Biotechnology). Blots were visualized with
ECL Western Blotting Detection reagents (GE Healthcare).
APC purification and Tim-2 ligand staining. Spleen and lymph node
cells were harvested from naive SJL/J, BALB/c, NOD, or C57BL/6 mice
(Jackson ImmunoResearch Laboratories); and activated with concanavalin A
(CD3 ), LPS (Sigma-Aldrich), and IFN-  (B220 , CD11b , CD11c ); and
immediately used for purification. Subsets were purified using column based
positive selection magnetic-activated cell sorting beads (Miltenyi Biotec).
B220  beads were used for the purification of B cells, CD11b  beads were
used for the purification of macrophage and dendritic populations, and
CD11c  beads were used for the purification of dendritic cells. CD4  T cells
were column purified by negative selection (R&D Systems). Cells were
stained with biotinylated hIgG (as a negative control), or biotinylated Tim-2.
Streptavidin-PE was used as the secondary detection reagent. All cells were
analyzed by flow cytometry using a Becton Dickinson FACSCalibur.
Proliferation assays. Female SJL/J mice (6–12 wk old) were injected s.c.
in each flank with 50  g PLP 139–151 peptide (HSLGKWLGHPDKF;
Quality Controlled Biochemicals) emulsified in CFA (Difco). Mice were in-
jected i.p. every other day (beginning day 0, and continuing through day 8)
with 100  g Tim-2 Ig, 100  g control hIgG, or 100  l PBS. Mice were
killed on day 10, and spleens harvested. Cells were plated at 5   105 cells/
well in 96-well plates (Falcon, Becton Dickinson) with PLP 139–151 added
at 0–100  g/ml for 48 h. Plates were pulsed with 1  Ci 3[H]-thymidine/
well for 16–18 h. Incorporation was measured using a Beta Plate scintillation
counter (PerkinElmer). The data are shown as mean cpm in triplicate wells.
For cell separation experiments, CD11b  and B220  cells were puri-
fied through positive selection as described above, and CD3  T cells were
purified using negative selection columns (R&D Systems) after depletion of
CD11b  and B220  cells. CD3  T cells were plated at 105 cells/well, and
CD11b  and B220  cells were plated at 2   105 cells/well.
Cytokine ELISAs. Cytokine production was measured for IL-2, IL-4,
IL-10, IFN- , and TNF-  by quantitative capture ELISA. In brief, capture
mAbs to mouse IL-2 (clone JES-1A12), IL-4 (clone BVD4-1D11), IL-10
(clone JES5-2A5), and IFN-  (clone R4-6A2) were from BD Biosciences.
Recombinant mouse cytokines (BD Biosciences) were used as standards.
Biotinylated rat mAbs to mouse IL-2 (clone JES6-5H4), IL-4 (clone
BVD6-24G2), IL-10 (clone SXC-1), IFN-  (clone XMG1.2), and TNF- 
(clone MP6-XT3) were used as the second antibody. Assays were devel-
oped with TMB microwell peroxidase substrate (Kirkegaard and Perry Lab-
oratories) and read at 450 nm using a Benchmark microplate reader (Bio-
Rad Laboratories).
Generation of Tim2 Ig fusion protein. The DNA sequence contain-
ing the extracellular domain of Tim-2 was amplified by PCR and cloned
into a vector containing the CD5 signal sequence and the human IgG1
constant region. NS.1 cells were transfected stably, and recombinant protein
was purified from supernatant using protein A chromatography.
Induction of experimental autoimmune encephalomyelitis. Fe-
male SJL mice (4–8 wk old; The Jackson Laboratory) were injected s.c. in
each flank with 50–75  g of PLP 139–151 peptide in CFA supplemented
with 400  g of Mycobacterium tuberculosis (Difco). Each mouse also was in-
jected i.v. with 100 ng of pertussis toxin (List Biological Laboratories) in 0.1
ml of PBS. Mice were injected i.p. on alternate days beginning at day 0 and
continuing for 8 d with 100  g Tim-2 Ig (endotoxin activity of 0.2 to 0.8
EU/mg) or 100  g control hIgG or 100  L PBS. Mice were examined
daily for signs of EAE, which were graded as follows: flaccid tail, 1; uneven
gait and impaired righting reflex, 2; total hindlimb paralysis, 3; fore- and
hindlimb paralysis, 4; and moribund, 5. Disease scores over the course of
the experiment (25 d) were totaled for each animal, and the mean for the
experimental group was expressed as a cumulative score. Significance was
established using the Student’s t test. At the peak of the disease or at the end
of the experiment, brains and spinal cords were removed, fixed in 10% for-
malin, and examined histopathologically for inflammation and demyelin-
ation. Inflammatory foci in meninges and parenchyma were counted by a
blinded observer as described previously (20). Mice were housed in a spe-TIM-2 REGULATES TH2 RESPONSES | Chakravarti et al. 444
cific pathogen-free, viral antibody–free animal facility at the Harvard Insti-
tutes of Medicine. All breeding and experiments were performed in accor-
dance with the guidelines of the Committee on Animals of Harvard
Medical School.
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